Literature DB >> 28182783

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Jesús Troya, Pablo Ryan, Esteban Ribera, Daniel Podzamczer, Victor Hontañón, Jose Alberto Terrón, Vicente Boix, Santiago Moreno, Pilar Barrufet, Manuel Castaño, Ana Carrero, María José Galindo, Ignacio Suárez-Lozano, Hernando Knobel, Miguel Raffo, Javier Solís, María Yllescas, Herminia Esteban, Juan González-García, Juan Berenguer, Arkaitz Imaz.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0164455.].

Entities:  

Year:  2017        PMID： 28182783      PMCID： PMC5300180          DOI： 10.1371/journal.pone.0172184

Source DB:  PubMed          Journal:  PLoS One        ISSN： 1932-6203            Impact factor:   3.240


  1 in total

1.  Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.

Authors:  Jesús Troya; Pablo Ryan; Esteban Ribera; Daniel Podzamczer; Victor Hontañón; Jose Alberto Terrón; Vicente Boix; Santiago Moreno; Pilar Barrufet; Manuel Castaño; Ana Carrero; María José Galindo; Ignacio Suárez-Lozano; Hernando Knobel; Miguel Raffo; Javier Solís; María Yllescas; Herminia Esteban; Juan González-García; Juan Berenguer; Arkaitz Imaz
Journal:  PLoS One       Date:  2016-10-11       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.